ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer

XIAOHONG LV1, YANG LI1, MING QIAN2, CHENGYUAN MA3, HONGYU JING1, ZHONGMEI WEN1 and DONGHUA QIAN1

1Department of Respiration, The First Hospital of Jilin University; 2Department of Prosthodontics, Stomatological Hospital, Jilin University; 3Department of Neurosurgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

Received August 24, 2013; Accepted February 24, 2014

DOI: 10.3892/mmr.2014.2029

Abstract. A disintegrin and metalloprotease (ADAM) 17 has been implicated in the tumor progression of various types of solid tumor; however, little is known about its role in non-small cell lung carcinoma (NSCLC). The present study evaluated whether the downregulation of ADAM17 affects cell proliferation, the cell cycle, cell migration and cell invasion in NSCLC. A recombinant lentiviral small hairpin RNA (shRNA) expression vector carrying ADAM17 was constructed and then infected into A549 cells, a human NSCLC cell line. Cell proliferation, cell cycle progression, cell migration and cell invasion were determined following the downregulation of ADAM17 by siRNA. It was revealed that downregulation of ADAM17 expression using an RNA silencing approach in A549 tumor cells significantly suppressed cell proliferation and invasion in vitro, and tumor growth in vivo. These data suggested that ADAM17 is an important regulator of the tumorigenic properties of human NSCLC and may be used as a potential anticancer therapeutic target in NSCLC.

Introduction

Lung cancer is the second most common cause of cancer-related mortality worldwide in males and females (1). Non-small cell lung carcinoma (NSCLC), which includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma accounts for >80% of lung cancer (2,3). The majority of patients presenting with NSCLC have advanced disease, which precludes curative treatment due to a lack of early diagnosis detection (4). Early detection and treatment may result in the identification of more patients with early central lung cancer and improve survival rates (1). Thus, it is crucial to develop novel molecular diagnostic markers and therapeutic targets for the treatment of NSCLC.

A disintegrin and metalloprotease (ADAM) 17 is a member of the disintegrin and metalloprotease gene family. This family encodes proteins that mediate cellular responses to environmental stress by interacting with a variety of cell surface proteins and regulating diverse cellular processes, including proliferation, extracellular matrix binding and ectodomain shedding (5-7). Previously, ADAM17 has been analyzed in various tumor entities and was revealed to be differentially expressed, partially conveying prognostic information (8,9). Previous studies demonstrated that ADAM17 is highly expressed in NSCLC and highly expressed ADAM17 correlates with shortened survival time, suggesting that ADAM17 may also become a useful predictive biomarker for the selection of adjuvant chemotherapy treatment of NSCLC (10). However, little is known about whether the downregulation of ADAM17 effects cell proliferation, cell invasion and the cell cycle in NSCLC, and its underlying molecular mechanisms. Thus, the present study assessed the feasibility of lentiviral vector-delivered small hairpin RNA (shRNA) against ADAM17 for the treatment of NSCLC in vitro and in vivo.

Materials and methods

Cell culture. The A549 human non-small cell lung cancer cell line was obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences, Shanghai Institute of Cell Biology (Shanghai, China). A549 lung tumor cells were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (FBS), glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 mg/ml) and amphotericin B (250 mg/ml; all from Invitrogen Life Technologies, Carlsbad, CA, USA) in 5% CO2 at 37°C.

Construction and transfection of pGCSIL-GFP-ADAM17. In order to inhibit the expression of ADAM17, an shRNA targeting the ADAM17 transcript was designed. The synthesized oligonucleotides containing a specific target sequence, a loop, the reverse complement of the target sequence, a stop codon for the U6 promoter and two sticky ends were cloned into the pGCSIL-GFP lentivirus vector according to the manufacturer’s instructions (Shanghai Gene Chem Co.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan was used. Cells without any treatment, cells treated only with negative siRNA and cells transfected with siRNAs were seeded in 96-well plates and kept at 37°C for 24, 48 and 72 h. The cells were then washed with PBS and incubated in 50 µl of 0.5 mg/ml MTT in culture medium at 37°C for 4 h. Following the addition of 100 µl isopropanol, the absorbance was read at 595 nm by an ELISA plate reader (Molecular Devices Corp., Sunnyvale, CA, USA). The mean proliferation of cells without any treatment was expressed as 100%.

Cell cycle analysis. A549 cells were treated with siRNA for 24 h in DMEM media containing 5% FBS. All cells were collected and 1x10⁶ cells were centrifuged 700 x g for 5 min, resuspended in ice-cold 70% ethanol and stored at -20°C until analysis. Washed cells were stained with 0.1% Triton X-100 in 0.01 M PBS with 50 µg/ml propidium iodide (Sigma) and 1 µg/ml RNase A (Invitrogen Life Technologies), and incubated at 37°C for 30 min in the dark. The samples of cells were then analyzed for DNA content by FACSscan flow cytometry (Beckman Coulter, Inc., Miami, FL, USA) and cell cycle phase distributions was analyzed with the Cell Quest acquisition software (BD Biosciences, Franklin Lakes, NJ, USA). Duplicates were performed in all experiments and experiments were performed on three occasions.

Cell migration assay. The migration assay was performed using a 12-well Boyden Chamber (Neuro Probe, Gaithersburg, MD, USA) with an 8-µm pore size. Approximately 1x10⁶ cells were seeded into the upper wells of the Boyden Chamber and incubated for 6 h at 37°C in medium containing 1% FBS. DMEM medium with 10% FBS was used as a chemotaxant in the bottom wells. Cells that did not migrate through the pores of the Boyden chamber were manually removed with a rubber swab. Cells that migrated to the lower side of the membrane were stained with hematoxylin and eosin and images were captured using an inverted microscope (Olympus, Tokyo, Japan).

Transwell invasion assay. The invasiveness of A549 cancer cells was assessed using 24-well Transwell plates (Corning Inc., Lowell, MA, USA). In brief, 2x10⁵ cells in DMEM media with 0.5% FBS were added to the upper chamber containing 8-mm pore polycarbonate coated with 1 µg/ml matrigel. The lower chamber was filled with media containing 5% FBS. Following 16 h of incubation, the upper surface of the membrane was scrubbed with a cotton-tipped swab. The invading cells on the lower side of the membrane were fixed and stained with 0.5% crystal violet. Images of the random fields (five per membrane) were captured at x40 magnification for calculating the cell number. In addition, cells were quantified by measuring the absorbance of dye extracts at 570 nm in 100 ml Sorenson's solution (0.9 mg trisodium citrate, 305 ml distilled water, 195 ml 0.1 NHCl and 500 ml of 90% ethanol). Duplicates were performed in all experiments and experiments were performed on five occasions.

Zymographic analysis. MMP-2 and MMP-9 enzymatic activities were measured by gelatin zymography. Conditioned media from cells (cultured without serum for 48 h) were collected
and concentrated 20-fold using a Centriprep YM-30 device (Millipore). Samples were then mixed with Laemmli loading buffer and electrophoresed on a gelatin containing 10% SDS-PAGE. Following electrophoresis, the gel was washed twice with wash buffer (50 mM Tris-HCl, pH 7.5; 100 mM NaCl and 2.5% Triton X-100), followed by a brief rinse in wash buffer without Triton X-100. The gel was then placed in incubation buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl, 10 mM CaCl$_2$, 0.02% NaN$_3$, 1 M ZnCl$_2$) at 37˚C for 24 h. The gel was then stained with Coomassie Blue R-250 and destained with destaining solution. A clear zone of gelatin digestion was representative of the MMP activity.

**Tumor xenograft model.** All animal experiments were performed in accordance with institutional guidelines, following a protocol approved by the Ethics Committees of the Disease Model Research Center, The First Hospital of Jilin University (Changchun, China). Male, nude mice (age, ~6-weeks) were maintained under specific pathogen-free (SPF) conditions and provided with food and water ad libitum. All the animals were fed with a normal pellet diet one week prior to the experimentation. *In vitro* cultured A549 cells were injected subcutaneously into mice. The tumor volume was calculated using the following formula: Volume = length x width$^2$ / 2. When tumors grew to an average volume of 75 mm$^3$, the mice were randomly divided into the siRNA group, control group (untreated group), NC group (n=10 in each group) and treated by administration of siRNA or NC plus PBS in a total volume of 20 µl (10 µl of the virus plus 10 µl of PBS) once a week for 21 days, respectively. When control mice started to succumb to their tumors, mice in all treatment groups were anesthetized by sodium pentobarbital (1.25 g/kg) after overnight fasting and decapitated. The tumors were then removed and directly embedded in an optimal cutting temperature compound in a deep freezer at -80˚C.

**Statistical analysis.** Statistical analysis between two samples was performed using Student's t-test. Statistical comparison of more than two groups was performed using one-way analysis of variance followed by Tukey's post hoc test. All data are expressed as the mean ± standard error of the mean.

**Results**

**ADAM17 silencing is detected at the mRNA and protein levels.** The lentivirus carrying the ADAM17 siRNA or scramble siRNA were transfected into A549 cells. ADAM17 gene expression was markedly decreased in A549 cells treated with siRNA at the mRNA and protein level (Fig. 1) compared with the controls (untreated cell) and scrambled-treated cells. qPCR analysis demonstrated a downregulation of ADAM17 expression in RNAi-mediated knockdown A549 cells when compared with the control cells and scrambled-treated cells (Fig. 1A). At the protein level, similar results were obtained by western blot analysis using an anti-ADAM17 antibody (Fig. 1B).

**ADAM17 silencing affects A549 cell proliferation and apoptosis.** To investigate whether siRNA affects A549 cell proliferation and apoptosis, A549 cells were treated with siRNA and negative siRNA for 24, 48 and 72 h. The antiproliferative and apoptotic effects of siRNA on A549 cells were examined by MTT and acridine orange assays, respectively. It was revealed that ADAM17 silencing was able to significantly inhibit the proliferation of A549 cells when compared with scrambled-treated cells and control cells (Fig. 2A). In addition, to determine the effects of A549 cell cycle progression following ADAM17 silencing, flow cytometry was performed in the present study. The percentage of cells in the siRNA therapy groups significantly increased at the G0/G1 phase compared with scrambled-treated cells and control cells. These results suggest that ADAM17 silencing is able to induce cell cycle arrest at the G0/G1 phase in A549 cells (Fig. 2B).

**ADAM17 silencing inhibits A549 cell invasion without affecting cell migration.** To analyze whether siRNA effects A549 cell migration, migration assays were performed using Boyden chambers. RNA-mediated ADAM17 silencing...
had no effect on A549 cell migration when compared with control cells (scrambled-treated cells and untreated cell; Fig. 3A). By contrast, RNAi-mediated ADAM17 knockdown in A549 cells markedly inhibited invasion *in vitro* when compared with scrambled-treated cells and control cells (Fig. 3B). Control cells (untransfected cell) and NCtransfected cells remained invasive and no statistically significant differences were identified.

**Silencing ADAM17 suppressed tumor growth *in vivo.* To investigate the effects of ADAM17 on tumor growth and metastasis in a nude mouse model, a xenograft assay was conducted by injecting the NC cells and ADAM17-silenced tumor cells subcutaneously into mice and comparing the growth rate of the solid tumors. It was revealed that tumor volume and weight was significantly slower for ADAM17 tumor cells compared with the control cells and NC cells following ADAM17 silencing (Fig. 4). These results indicated that the suppression of ADAM17 expression in lung tumor cells markedly suppressed their tumorigenicity in mice.

**Preliminary mechanisms involved in the regulation of cell proliferation and invasion by ADAM17.** To investigate the preliminary mechanisms involved in the regulation of cell proliferation and invasion by ADAM17 *in vitro*, the activation of cyclin D1, cyclin D3 and p21 in ADAM17 silencing were analyzed by western blot analysis and compared with that of control cells transfected with empty vectors. As shown in Fig. 5A, ADAM17 silencing significantly inhibited cyclin D1 and cyclin D3 expression and increased p21 expression in the A549 tumor cells.

In order to investigate the mechanisms involved in the inhibition of the invasion ability of RNAi-mediated ADAM17 silencing of A549 cells, zymography assays were performed to evaluate the activity of MMP-2 and MMP-9. Data demonstrated that ADAM17 silencing exhibited much lower MMP-9 activity compared with its control cells as determined by zymography assays (Fig. 5B).

**Discussion**

ADAMs are known as ectodomain sheddases, a function of their metalloprotease domains and is a member of the superfamily of Zn-dependent metalloproteinases (12,13). ADAMs are therefore important in the remodeling or processing of cell membrane proteins. Several of the substrates processed by ADAMs, particularly by ADAM10 and ADAM17, have been implicated in the pathogenesis or progression of cancer (14,15). Previous
studies have demonstrated that ADAM17 is involved in invasion and proliferation (16,17). The results of the present study are in line with this theory and demonstrate that ADAM17 silencing suppresses A549 tumor proliferation and invasion in vitro and tumor growth in vivo. The data further demonstrated that ADAM17 is important in tumor progression.

ADAM17 sheds a variety of important cell surface molecules, including cytokines and adhesion molecules (18), which are important in cell proliferation and invasion. It has been demonstrated that ADAM17-mediated epidermal growth factor receptor ligand cleavage enhances the proliferation and survival of squamous cell carcinoma cells as well as lung cancer cells (19,20). The present study employed an A549 human lung cancer cell line to investigate the effect of ADAM17 on lung cancer proliferation, cell cycle progression and invasion in vitro. The downregulation of ADAM17 expression was established by siRNA transfection. To assess A549 cell viability and proliferation, an MTT assay was employed. The data demonstrated that a reduction of ADAM17 by shRNA significantly decreased tumor cell proliferation when compared with the control. In addition, the present study also demonstrated that ADAM17 knockdown induces cell cycle arrest at the G0/G1 transition in NSCLC cells. To investigate the exact mechanism, cell cycle-related proteins were analyzed, after silencing ADAM17, by western blot analysis. The p21 protein is a widely accepted cell cycle regulator, as a cyclin dependent kinase (CDK) inhibitor and a negative regulator in the G1/S transition (21). In the present study, compared with the control cells transfected with empty vectors, p21 expression was markedly increased after silencing ADAM17. Whereas, cyclin D1 or cyclin D3 expression decreased following silencing. These data demonstrated that ADAM17 downregulation was able to effect p21, cyclin D3 and cyclin D1 levels to reduce lung carcinoma cell proliferation.

The progression of malignant tumors results from the invasion of the primary tumor to a secondary site, causing metastasis in a multistep process that requires cell-cell and cell-matrix interactions within the host tissue. These interactions lead to the production, release and activation of a variety of cytokines and growth factors and subsequent generation of signals to directly or indirectly promote tumor growth and survival (22). Different proteases have been implicated in these processes, including MMPs, ADAMs and a disintegrin and metalloprotease with thrombospondin motifs (23,24). Due to the strong involvement of ADAM17 in the metastatic process, the present study demonstrated that ADAM17 silencing significantly inhibited the invasion capacity of A549 human lung cancer cells using a matrigel invasion assay, which suggests that this protein is important in cell invasion. Furthermore, it was revealed that ADAM17 silencing was able to inhibit MMP-2 and MMP-9 expression by a zymographic assay indicating reduced cell invasion.

In conclusion, the present study demonstrated that ADAM17 silencing significantly suppressed cell proliferation and invasion in vitro, and tumor growth in vivo. ADAM17 is
an important regulator of the tumorigenic properties of human NSCLC and may be used as a potential anticancer therapeutic target in NSCLC. Considering the significance of cell invasion in metastatic progression, ADAM17 may be a key target for the design of drugs involved in the treatment or prevention of NSCLC cancer.

References